Understanding Triglyceride Deposit Cardiomyovasculopathy (TGCV)

Being diagnosed with a rare condition like Triglyceride Deposit Cardiomyovasculopathy (TGCV) can be overwhelming and confusing. Because this disease was only recently identified—largely through research and specialized registries in Japan—many doctors outside of specialized centers may not be familiar with it yet ^[1]. It is a complex metabolic heart condition, but understanding how it affects your heart cells can help you work more effectively with your medical team.

What is TGCV?

TGCV is an adult-onset condition where the cells in your heart muscle (cardiomyocytes) and the walls of your blood vessels (vascular smooth muscle) lose the ability to break down intracellular triglyceride droplets—fats stored inside the cells themselves ^[1][2].

In a healthy heart, these stored fats are broken down into fatty acids that the heart uses as a major “fuel” to keep pumping. In TGCV, the “engine” of the cell cannot access this stored fuel. This leads to two major problems:

1. Energy Failure: Because the heart cannot burn its stored fuel source, it lacks the energy to pump effectively, contributing to heart failure ^[1].
2. Fat Buildup (Steatosis): The unused triglycerides accumulate inside the heart and blood vessel cells, causing damage and contributing to a unique, severe form of coronary artery disease ^[1][2].

Note: TGCV is not caused by eating too much fat. Your routine blood triglyceride levels and body weight (BMI) may be perfectly normal even if your heart cells are struggling to process intracellular fats. However, standard cardiovascular risk factors like high LDL cholesterol or high blood pressure are still important to manage alongside TGCV.

Why Does This Happen?

The breakdown of stored triglycerides is managed by an enzyme called ATGL (Adipose Triglyceride Lipase), which is produced by the PNPLA2 gene ^[1][3].

• Primary TGCV (P-TGCV): This is the genetic form of the disease. It occurs when a person has biallelic (two copies) pathogenic mutations in the PNPLA2 gene that prevent the ATGL enzyme from working correctly ^[1][3]. This form often appears earlier in life (as a trend, typically in the 30s) and may also involve skeletal muscle weakness ^[1][4].
• Idiopathic TGCV (I-TGCV): This form is diagnosed when a patient has the clinical symptoms and cellular defects of TGCV but no identified PNPLA2 mutation ^[1][5]. While the exact cause is still being researched, these patients still show a significant loss of ATGL enzyme activity ^[6]. I-TGCV typically appears later (often in the 50s) and is more common than the primary form in the Japanese registries ^[1].

How Rare is TGCV?

TGCV is considered an extremely rare or “emerging” disease. Because it requires specialized imaging to evaluate, many cases likely go undetected ^[1].

• In Japan: Based on specific observational cohorts as of late 2024, approximately 15 primary cases and nearly 1,000 idiopathic cases have been clinically diagnosed ^[1].
• Globally: While cases have been reported worldwide, the total global incidence is not yet well-defined. It is sometimes found in patients who already have other conditions, such as those on long-term hemodialysis or those with unexplained chronic heart failure ^[7][8].

Diagnosis: The “Washout” Test

Standard tests like blood triglyceride panels do not diagnose TGCV ^[1]. Instead, doctors use a specialized nuclear medicine scan called BMIPP scintigraphy as an important functional test ^[2][9].

In this test, a tracer is injected to see how your heart handles fatty acids. Doctors measure the washout rate—how quickly the heart processes and clears the tracer. Under Japanese diagnostic criteria, a washout rate of less than 10% strongly supports the diagnosis, provided other causes (like old heart attacks or ischemia) are ruled out ^[1][9].

Managing Life with TGCV

While TGCV is rare and lacks a simple cure, you are not without options. Management typically involves two parallel paths:

1. Standard Heart Care: Your team will use established treatments for heart failure, arrhythmias (irregular heartbeats), and coronary artery disease ^[1]. Because TGCV can complicate procedures like stents, your doctor may consult with a TGCV specialist ^[10].
2. Specialized Metabolic Approaches: Research is ongoing into treatments that provide the heart with alternative fuel sources. One such investigational approach involves tricaprin (a medium-chain triglyceride, CNT-01), which is being studied to see if bypassing the broken ATGL pathway can help the heart cells ^[11][12]. Early phase trials showed improvements in metabolic markers, though clinical symptom benefits are not yet proven ^[12][13].

Because this is a rare condition, participating in an International Registry [NCT02918032]^[5] can help experts worldwide better understand the disease. Talk to your cardiologist about coordinating care with a specialized research center.